Ferring Pharmaceuticals, headquartered in Saint-Prex, Switzerland, is the new member of SWISSCAM


Date : 2017-10-06 15:43:18
Founded in the 1950s, the company has more than 6,000 employees, branches established in more than 60 countries around the world, and its treatments are available in more than 110 countries.

The company develops innovative products within the healthcare segments of reproduction, urology, gastroenterology, endocrinology and orthopedics. The activities related to research and development are linked to personalized care and treatments which work as the body itself, i.e. physiologically, and thus make it possible for doctors to combat a wide range of ailments without altering the natural balance of the organism.

In Brazil, Ferring has been present for 25 years and has about 100 employees. The company is also investing in innovation locally. At the beginning of July Ferring Pharmaceuticals Brazil launched a research and development financing project for new products called Ferring Brazil Innovation Grants Program.

According to Alexandre Seraphim, General Manager of Ferring Brazil, "this program values the science of our country and the capacity of our scientists. This initiative confirms Ferring's strategic vision in Brazil. We are very proud of this project."

The program is aimed at identifying and selecting innovative projects developed in this country in areas of interest to Ferring Brazil. The program's specific objectives are:
• To identify and select promising innovation projects being developed in Brazil;
• To finance with up to BRL 300,000 each project that is approved out of a total of BRL 1 million worth of research funding; and
• To foster partnerships of co-development and/or absorption of new technologies.

The company will seek partnerships with universities and other local institutions. The objective of the investments is to establish a technological hub in Brazil, which is a strategic country for Ferring.